Literature DB >> 9590726

Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention.

.   

Abstract

These recommendations update information concerning the vaccine and antiviral agents available for controlling influenza during the 1998-99 influenza season (superseding MMWR 1997;46[No. RR-9:1-25]). The principal changes include a) information about the influenza virus strains included in the trivalent vaccine for 1998-99, b) more detailed information about influenza-associated rates of hospitalization, and c) updated information on the possible relationship between Guillain-Barre syndrome and influenza vaccination.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9590726

Source DB:  PubMed          Journal:  MMWR Recomm Rep        ISSN: 1057-5987


  28 in total

Review 1.  Individual and community impact of influenza.

Authors:  A S Monto
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

Review 2.  Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence.

Authors:  M J Postma; R M Baltussen; M L Heijnen; L T de Berg; J C Jager
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

Review 3.  Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence.

Authors:  Maarten J Postma; Paul Jansema; Marianne L L van Genugten; Marie-Louise A Heijnen; Johannes C Jager; Lolkje T W de Jong-van den Berg
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Influenza vaccination in Alberta long-term care facilities.

Authors:  M L Russell
Journal:  CMAJ       Date:  2001-05-15       Impact factor: 8.262

5.  The association between influenza immunization coverage rates and hospitalization for community-acquired pneumonia in Alberta.

Authors:  Yan Jin; Keumhee C Carriere; Gerry Predy; David H Johnson; Thomas J Marrie
Journal:  Can J Public Health       Date:  2003 Sep-Oct

6.  Breaking the barriers to childhood influenza vaccination.

Authors:  M M Ipp
Journal:  Paediatr Child Health       Date:  1998-09       Impact factor: 2.253

7.  Efficacy of the influenza vaccine in patients with malignant lymphoma.

Authors:  Joseph J Mazza; Steven H Yale; Jodi R Arrowood; Cory E Reynolds; Ingrid Glurich; Po-Huang Chyou; James G Linneman; Kurt D Reed
Journal:  Clin Med Res       Date:  2005-11

8.  The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years.

Authors:  K L Nichol; M Goodman
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

9.  A pharmacoeconomic model for the treatment of influenza.

Authors:  J A Mauskopf; S C Cates; A D Griffin
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

Review 10.  Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

Authors:  G He; J Massarella; P Ward
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.